Niki BioSolutions Shareholders’ Equity Growth & History (NIKI)
Niki BioSolutions's shareholders’ equity was $23.1M for fiscal 2025.
View full Niki BioSolutions company overviewNiki BioSolutions annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $23.1M | $2.0M | +9.37% |
| 2024 | 2024-12-31 | $21.1M | −$3.7M | −14.94% |
| 2023 | 2023-12-31 | $24.8M | $9.1M | +58.13% |
| 2022 | 2022-12-31 | $15.7M | −$7.9M | −33.44% |
| 2021 | 2021-12-31 | $23.6M | −$18.2M | −43.57% |
| 2020 | 2020-12-31 | $41.8M | $25.5M | +155.69% |
| 2019 | 2019-12-31 | $16.4M | −$16.8M | −50.59% |
| 2018 | 2018-12-31 | $33.1M | $2.9M | +9.49% |
| 2017 | 2017-12-31 | $30.2M | — | — |
Niki BioSolutions quarterly shareholders’ equity
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $23.1M | $2.0M | +9.37% |
| Q3 2025 | 2025-09-30 | $22.5M | — | — |
| Q2 2025 | 2025-06-30 | $23.1M | $478,651 | +2.11% |
| Q4 2024 | 2024-12-31 | $21.1M | −$3.7M | −14.94% |
| Q2 2024 | 2024-06-30 | $22.7M | $811,244 | +3.71% |
| Q4 2023 | 2023-12-31 | $24.8M | $9.1M | +58.13% |
| Q2 2023 | 2023-06-30 | $21.8M | −$803,042 | −3.55% |
| Q4 2022 | 2022-12-31 | $15.7M | −$7.9M | −33.44% |
| Q2 2022 | 2022-06-30 | $22.6M | −$8.9M | −28.12% |
| Q4 2021 | 2021-12-31 | $23.6M | −$18.2M | −43.57% |
| Q2 2021 | 2021-06-30 | $31.5M | $11.7M | +58.82% |
| Q4 2020 | 2020-12-31 | $41.8M | $25.5M | +155.69% |
| Q2 2020 | 2020-06-30 | $19.8M | — | — |
| Q4 2019 | 2019-12-31 | $16.4M | −$16.8M | −50.59% |
| Q4 2018 | 2018-12-31 | $33.1M | $2.9M | +9.49% |
| Q4 2017 | 2017-12-31 | $30.2M | — | — |
Niki BioSolutions shareholders’ equity trends
Over the last five fiscal years, Niki BioSolutions's shareholders’ equity decreased from $41.8M to $23.1M, a change of −$18.7M. The latest reported quarter, Q4 2025, shows $23.1M.
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Niki BioSolutions source filings ↗